List of Excipients in Branded Drug STRATTERA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	STRATTERA	atomoxetine hydrochloride	0002-3227	DIMETHICONE
Eli Lilly and Company	STRATTERA	atomoxetine hydrochloride	0002-3227	GELATIN
Eli Lilly and Company	STRATTERA	atomoxetine hydrochloride	0002-3227	SODIUM LAURYL SULFATE
Eli Lilly and Company	STRATTERA	atomoxetine hydrochloride	0002-3227	STARCH, CORN

Strattera Excipient Strategy and Commercial Opportunities for Atomoxetine

Last updated: August 14, 2026

Strattera, the original brand of atomoxetine hydrochloride, has limited opportunity for premium pricing based on the active ingredient because U.S. market exclusivity and core patent protection have expired. The strongest commercial opportunities are in pediatric-friendly delivery, dose flexibility, swallowability, excipient simplification, supply reliability, and differentiated global formulations. Atomoxetine is a nonstimulant ADHD medicine with an established safety and efficacy profile, making formulation improvements more commercially credible than a new active-ingredient positioning.

What is Strattera and how is atomoxetine formulated?

Strattera contains atomoxetine hydrochloride, a selective norepinephrine reuptake inhibitor approved for the treatment of attention-deficit/hyperactivity disorder. The U.S. product is supplied as immediate-release hard gelatin capsules in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, and 100 mg strengths.[1]

The capsule formulation uses standard solid-oral excipients. The U.S. prescribing information identifies inactive ingredients that include pregelatinized starch, dimethicone, gelatin, sodium lauryl sulfate, titanium dioxide, and capsule-coloring agents such as iron oxides and FD&C dyes. The exact colorant composition varies by capsule strength.[1]

Attribute	Strattera / atomoxetine
Active ingredient	Atomoxetine hydrochloride
Pharmacologic class	Selective norepinephrine reuptake inhibitor
FDA dosage forms	Immediate-release capsules
U.S. strengths	10, 18, 25, 40, 60, 80, 100 mg
Primary population	Pediatric, adolescent, and adult ADHD patients
Administration	Once daily or divided twice-daily dosing
Key metabolic pathway	CYP2D6
Brand developer	Eli Lilly and Company
Current competitive status	Generic atomoxetine competition
Primary formulation opportunity	Pediatric and swallowing-friendly delivery

The existing capsule format is technically straightforward. The commercial challenge is that the active ingredient is already available from multiple generic manufacturers, while atomoxetine has pharmacokinetic and safety constraints that limit indiscriminate reformulation.

What excipients are used in Strattera capsules?

Strattera's excipient system supports capsule manufacture, powder flow, content uniformity, capsule integrity, and acceptable dispersion after ingestion. It is not designed as a modified-release platform.

Pregelatinized starch

Pregelatinized starch is likely the principal diluent and disintegrant. It can improve powder compressibility and flow while supporting rapid capsule-content dispersion. A generic manufacturer could evaluate alternative starch grades, microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate, or co-processed excipients.

The commercial value of substitution would depend on:

• Blend uniformity at low dose strengths
• Flow through high-speed capsule equipment
• Moisture sensitivity
• Dissolution equivalence
• Supply cost and regional availability
• Compatibility with colorants and lubricants

At 10 mg and 18 mg, the active load is low relative to the total fill weight. Excipient selection therefore has a disproportionate effect on content uniformity and manufacturing economics.

Sodium lauryl sulfate

Sodium lauryl sulfate can function as a wetting agent and improve dispersion of hydrophobic drug particles. Atomoxetine hydrochloride is a salt, but wetting performance can still affect dissolution and batch-to-batch consistency.

A reformulator could assess lower levels of sodium lauryl sulfate or alternative surfactants. The objective would be to reduce potential gastrointestinal sensitivity while maintaining dissolution. Candidates may include polysorbates, poloxamers, sodium docusate, or nonionic wetting systems, subject to dose, local tolerance, and regulatory precedent.

The strongest development case would be a lower-irritancy formulation supported by comparative dissolution, biowaiver justification where available, and clinical tolerability data.

Dimethicone

Dimethicone is used as a processing or anti-foaming aid. Its level is generally low, but its presence may matter in excipient-simplification programs. Removal would require confirmation that capsule manufacture, powder handling, and dissolution remain unchanged.

Gelatin

Gelatin provides the capsule shell. It creates several commercial constraints:

• Animal-origin labeling requirements
• Halal and kosher certification requirements
• Vegetarian and vegan market limitations
• Cross-border regulatory documentation
• Potential supply-chain exposure to gelatin shortages

A hydroxypropyl methylcellulose or pullulan capsule could support a differentiated "vegetarian capsule" or animal-origin-free position. This change would require evaluation of moisture transmission, shell brittleness, dissolution, stability, printing, and fill compatibility.

Titanium dioxide and colorants

Colorants provide strength identification and reduce medication errors. Removing titanium dioxide or replacing synthetic dyes may support clean-label positioning, pediatric acceptability, or jurisdiction-specific compliance. The tradeoff is visual differentiation and manufacturing simplicity.

A colorant change is not automatically commercially meaningful. The product must retain clear strength identification across all markets, especially because atomoxetine is available in multiple strengths and dosing errors can have clinical consequences.

What excipient strategy has the highest commercial potential?

The best near-term strategy is a modular platform rather than a single reformulation. A manufacturer could develop multiple atomoxetine presentations from a common powder blend, reducing manufacturing complexity.

Strategy	Patient value	Regulatory burden	Commercial potential
Vegetarian capsule shell	Moderate	Moderate	Moderate
Dye-free capsule	Moderate	Low to moderate	Moderate
Reduced-excipient capsule	Low to moderate	Moderate	Low to moderate
Sprinkle capsule	High	Moderate to high	High
Oral powder for reconstitution	High	High	High
Oral solution	High for young children	High	High
Orodispersible tablet	Moderate to high	High	Moderate to high
Modified-release formulation	Potentially high	High	High but technically complex
Smaller capsule or mini-capsule	Moderate	Moderate	Moderate
Taste-masked multiparticulate product	High	High	High

The most attractive products address a known limitation of capsules: children may have difficulty swallowing them. The label also warns that capsules should not be opened because atomoxetine can irritate the eye. This creates a practical unmet need for a dosage form that delivers the contents without requiring capsule opening.[1]

What formulations could improve atomoxetine commercial positioning?

Sprinkle capsules

A sprinkle formulation could contain coated multiparticulates that are emptied onto soft food without exposing caregivers to atomoxetine powder. The product would need to prevent direct contact with the active ingredient and preserve dose uniformity.

Potential technologies include:

• Enteric or polymer-coated pellets
• Taste-masked drug-loaded particles
• Multiparticulate hard capsules
• Microtablets
• Drug-resin complexes
• Lipid-coated particles

A sprinkle capsule is likely more commercially practical than a conventional powder capsule because it can address swallowing while avoiding a free-powder handling problem.

Oral solution

An oral solution could serve younger children and patients unable to swallow capsules. Its main technical risks are taste, chemical stability, microbial control, dose-measurement accuracy, and compatibility with common dosing syringes.

Atomoxetine has a bitter pharmaceutical taste profile that would likely require a robust flavor and sweetener system. Candidate excipients may include:

• Sucralose or acesulfame potassium
• Sorbitol, glycerin, or maltitol
• Citrate or phosphate buffers
• Flavor systems
• Chelating agents
• Preservatives where necessary
• Viscosity modifiers

A sugar-free product would be commercially preferable for chronic pediatric use. Preservative-free unit-dose packaging could provide a second premium position, particularly for patients with preservative sensitivity or for institutional use.

Orodispersible tablets

An orally disintegrating tablet could eliminate the need for water and improve administration outside the home. The formulation must overcome atomoxetine's taste and achieve sufficient dose uniformity across strengths.

The principal technical issue is dose size. The 80 mg and 100 mg strengths may require larger tablets, multilayer designs, or a multiparticulate system. Low-dose strengths are better suited to orally disintegrating technology.

Modified-release formulations

Strattera is an immediate-release product that can be administered once daily or in divided doses. A controlled-release formulation could seek to reduce peak-related adverse effects, simplify administration, or provide more consistent symptom control.

The development burden is materially higher than for a conventional generic. A modified-release product would require:

• New pharmacokinetic characterization
• Comparative exposure analysis
• Dose-conversion studies
• Food-effect assessment
• Potential clinical efficacy bridging
• New dissolution specifications
• Abuse-deterrence and dose-dumping assessment

Atomoxetine is not a controlled substance, so abuse deterrence is not the primary value proposition. The stronger rationale would be tolerability and adherence.

How do excipients affect atomoxetine safety and pharmacokinetics?

Atomoxetine exposure is strongly influenced by CYP2D6 metabolism. Poor metabolizers and patients receiving strong CYP2D6 inhibitors can have substantially higher atomoxetine exposure than extensive metabolizers.[1]

Excipient changes cannot be evaluated solely through routine dissolution. A formulation that changes the rate of absorption could affect peak concentration and tolerability even if total exposure remains similar. Relevant development tests include:

• Comparative dissolution across physiologic pH ranges
• Particle-size characterization
• In vitro permeability where appropriate
• Food-effect testing
• Single-dose pharmacokinetic comparison
• Assessment of Cmax, Tmax, AUC, and half-life
• Evaluation in CYP2D6 extensive and poor metabolizer populations where clinically relevant

The formulation should avoid excipients that create clinically meaningful gastrointestinal effects in a pediatric population. High polyol loading may cause diarrhea or abdominal discomfort. Surfactants and acidic flavor systems can affect palatability and tolerability. Preservatives may be acceptable in conventional liquid products but less attractive in chronic pediatric therapy.

What FDA regulatory pathway applies to an atomoxetine reformulation?

A conventional generic capsule can generally use the ANDA pathway if it demonstrates pharmaceutical equivalence and bioequivalence to the reference listed drug. The FDA Orange Book identifies approved reference products and therapeutic-equivalence information for atomoxetine products.[2]

A materially different dosage form would usually require a different regulatory strategy.

Product concept	Likely U.S. pathway
Same capsule strength with different excipients	ANDA, subject to equivalence requirements
Vegetarian capsule shell	ANDA if equivalence remains demonstrable
Dye-free capsule	ANDA if formulation and equivalence requirements are met
Sprinkle multiparticulate capsule	Potentially 505(b)(2) or ANDA depending on sameness
Oral solution	Generally 505(b)(2), unless an appropriate reference and equivalence pathway applies
Orally disintegrating tablet	Usually 505(b)(2) or a product-specific generic pathway
Modified-release product	Usually 505(b)(2) or new drug application strategy
New pediatric liquid with clinical differentiation	505(b)(2) is likely

The principal regulatory risk is that a formulation marketed as a clinically differentiated product may not qualify for the lowest-cost generic pathway. A product developer must decide early whether the objective is lowest manufacturing cost, incremental formulation differentiation, or a proprietary lifecycle product.

What is the Orange Book and patent status of Strattera?

Strattera's U.S. market protection has expired. Atomoxetine generic products have been approved, confirming that the brand's core exclusivity no longer prevents generic entry.[2]

The original U.S. exclusivity profile included:

• New chemical entity exclusivity after the 2002 approval
• Pediatric exclusivity associated with postmarketing pediatric studies
• Historical patent protection covering atomoxetine and related pharmaceutical use

The relevant commercial conclusion is that current value does not depend on defending the original Strattera capsule against generic entry. It depends on creating a new, protectable product profile.

Potential new intellectual-property positions could cover:

• Multiparticulate architecture
• Taste-masking compositions
• Specific polymer coatings
• Low-dose pediatric formulations
• Oral liquid stability systems
• Preservative-free unit-dose packaging
• New capsule-shell systems
• Modified-release profiles
• Specific methods for reducing peak-related adverse effects
• Manufacturing processes that improve content uniformity

A patent directed only to a routine excipient substitution would face vulnerability under obviousness standards. Stronger protection would require a defined technical problem, a non-obvious formulation solution, and data showing an unexpected benefit.

When does atomoxetine lose exclusivity, and what does that mean commercially?

Atomoxetine lost effective U.S. exclusivity years ago. The commercial impact is visible in the availability of multiple generic strengths and manufacturers. A new entrant cannot rely on the Strattera brand name alone to obtain premium pricing.

The market supports four distinct commercial models:

1. Low-cost generic capsules
   The objective is manufacturing efficiency, reliable supply, and broad formulary access.

2. Pediatric-friendly formulation
   The objective is to improve administration and adherence for children who cannot swallow capsules.

3. Premium clean-label product
   The product may use vegetarian capsules, reduced colorants, sugar-free liquid, or preservative-free packaging.

4. Specialist or channel-focused product
   The product may target hospitals, pediatric clinics, Medicaid populations, schools, or international markets with tailored packaging and dosing devices.

The second model has the clearest potential for meaningful differentiation. The fourth may produce defensible commercial niches even without broad retail dominance.

What generic entry risks exist for a new atomoxetine product?

Generic competition creates a low-price reference point. A differentiated product must justify higher cost through measurable patient or caregiver value.

Key risks include:

• Substitution by pharmacists where therapeutic-equivalence codes permit it
• Low willingness to pay for nonclinical excipient changes
• Pediatric prescriber inertia
• Formulary exclusion
• Short product life if formulation patents are narrow
• Limited clinical evidence for improved adherence
• Manufacturing complexity in multiparticulate systems
• Taste failure in liquid or orally disintegrating products
• Dose-measurement errors with liquid formulations
• Supply competition from established generic manufacturers

A new product should target a clear failure mode, such as inability to swallow, poor palatability, capsule-opening behavior, or inconsistent administration. "Free from" claims alone are unlikely to support strong pricing unless linked to a recognized patient need.

How does atomoxetine compare with competing ADHD medicines?

Atomoxetine competes with stimulant products such as methylphenidate and amphetamine formulations, as well as nonstimulants including viloxazine extended-release and guanfacine extended-release.

Product category	Main formulation advantage	Main atomoxetine opportunity
Immediate-release stimulants	Low cost and dose flexibility	Noncontrolled, pediatric-friendly delivery
Extended-release stimulants	Once-daily dosing	Nonstimulant positioning and alternative mechanism
Guanfacine ER	Once-daily nonstimulant dosing	Liquid, sprinkle, or flexible atomoxetine administration
Viloxazine ER	Extended-release nonstimulant	Established atomoxetine experience and generic economics
Atomoxetine capsules	Broad strength range	Improved swallowability, taste, and dosing flexibility

Atomoxetine's noncontrolled status can simplify prescribing, dispensing, inventory management, and school administration compared with controlled stimulants. A reformulated product could use that operational advantage in pediatric and institutional channels.

Which manufacturing and IP barriers matter most?

The main manufacturing barrier is not synthesis of atomoxetine. It is development of a stable, palatable, dose-accurate dosage form that remains bioequivalent or clinically bridgeable.

Capsule products

Capsules have low technical risk but limited differentiation. Critical manufacturing controls include blend uniformity, low-dose assay precision, capsule fill-weight control, and colorant consistency.

Liquid products

Liquids create higher risk from:

• Precipitation
• pH drift
• Oxidation
• Microbial growth
• Container adsorption
• Dose-device compatibility
• Taste masking
• In-use stability

Multiparticulates

Multiparticulate products may provide the best balance of patient value and patentability. Their risks include coating uniformity, pellet fracture, dose segregation, scale-up, and release-profile variability.

Intellectual property

A robust estate would combine composition claims with process and use claims. A single broad claim to a familiar excipient may not provide durable protection. The commercial value increases when the formulation has measured advantages in palatability, pharmacokinetic control, stability, or adherence.

What licensing deals and partnership opportunities exist?

The most likely partnership targets are:

• Capsule-shell manufacturers with vegetarian or pullulan platforms
• Pediatric drug-delivery companies
• Multiparticulate coating specialists
• Taste-masking technology providers
• Contract manufacturers with oral-liquid expertise
• Generic companies seeking a differentiated 505(b)(2) product
• Regional pharmaceutical companies with pediatric distribution networks

A licensing transaction would be strongest where the technology has already been demonstrated with atomoxetine or a closely related low-dose, bitter active ingredient. A platform licensed without drug-specific data would carry greater development and freedom-to-operate risk.

Key Takeaways

• Strattera contains atomoxetine hydrochloride in immediate-release hard gelatin capsules.
• The principal excipients include pregelatinized starch, dimethicone, gelatin, sodium lauryl sulfate, titanium dioxide, and capsule colorants.
• Core Strattera exclusivity has expired, and generic atomoxetine is established in the U.S. market.
• Routine excipient substitution offers limited premium potential.
• The strongest opportunities are sprinkle multiparticulates, oral liquids, orally disintegrating products, and vegetarian or animal-origin-free capsules.
• Pediatric administration is the central commercial opportunity.
• Atomoxetine's CYP2D6 metabolism makes pharmacokinetic bridging important for any formulation that changes absorption rate.
• A differentiated product is more likely to require a 505(b)(2) strategy than a standard ANDA.
• Strong patent positions should focus on delivery architecture, taste masking, stability, release control, or demonstrated clinical benefits.
• Generic launch risk is high for conventional capsules and lower for products addressing swallowing, palatability, or administration problems.

FAQs

Can atomoxetine capsules be opened and mixed with food?

The Strattera labeling advises against opening capsules because atomoxetine can irritate the eyes. A purpose-built sprinkle formulation would be safer than instructing caregivers to manipulate standard capsules.[1]

Is there a commercial opportunity for a sugar-free atomoxetine liquid?

Yes. A sugar-free liquid could target young children and patients with swallowing difficulties, but it would require strong taste masking, chemical and microbiological stability, an accurate dosing device, and an appropriate regulatory pathway.

Would a vegetarian atomoxetine capsule qualify for patent protection?

A vegetarian capsule shell alone may be difficult to protect broadly if the substitution is routine. Patent strength would improve if the shell produced an unexpected stability, dissolution, supply, or patient-adherence benefit.

Is atomoxetine suitable for an extended-release formulation?

It is technically suitable for extended-release development, but the commercial case must justify the additional clinical and regulatory burden. The most credible claims would involve tolerability, smoother exposure, or adherence rather than abuse deterrence.

Which atomoxetine formulation has the best licensing value?

A taste-masked, multiparticulate sprinkle product has the strongest licensing profile because it addresses pediatric administration, can support proprietary formulation claims, and may be scalable across multiple dose strengths.

References

1. Eli Lilly and Company. (2023). Strattera (atomoxetine hydrochloride) capsules prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.